Clinical trials: Recurrent Major Depression
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Episode
Retrospective Observational Study DIANA Study
This Non-Interventional Study (NIS) is intended to evaluate the duration of treatment with an initial antidepressant taken as monotherapy in patients in whom treatment was changed because of suboptimal response at physician's…
- Trial name
- DIANA (NCT01976793)
- Where
- 8 sites in Russia
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Recurrent, in Remission
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to…
- Trial name
- NCT05423275
- Testing
- Negative ion therapy, Light therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
The purpose of the study is to explore the Tolerability and Safety of the H-Coil deep Transcranial Magnetic Stimulation (TMS) in combination with Serotonin Selective Reuptake Inhibitor (SSRI) for Subjects with Major Depression…
- Trial name
- NCT01361815
- Testing
- H-Coil Deep TMS in combination with SSRIs
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Brainsway
Major Depressive Disorder, Chronic Major Depression, Recurrent
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective…
- Trial name
- Re-EMBARC (NCT05892744)
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas at Austin
Depression, Major Depressive Disorder
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression
Depression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the…
- Trial name
- NCT00744406
- Testing
- Cognitive Behavioral Therapy, Interpersonal Therapy, Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
MemFlex to Prevent Depressive Relapse
A wealth of research has demonstrated that they way in which the investigators recall our personal, autobiographical memories is influential in the course of depression.
- Trial name
- NCT02614326
- Testing
- Autobiographical Memory Flexibility (MemFlex) training, Psychoeducation
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Medical Research Council Cognition and Brain Sciences Unit
Late-life Depression, Major Depressive Disorder
Cognitive Behavioural Therapy for the Treatment of Late Life Depression
This study addresses the unmet medical problem of insufficient treatment of late life depression (LLD). Compared with depression in early adulthood, treatment options of LLD are limited.
- Conditions
- Late-life Depression, Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent
- Trial name
- CBTlate (NCT03735576)
- Testing
- Psychotherapy, Questionnaires, Magnetic Resonance Imaging
- Where
- 7 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University of Cologne
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Major Depressive Disorder
Study of Mindfulness-Based Cognitive Therapy
Research aimed at assessing changes in depressogenic thinking and the ability to disengage from depressogenic thinking following Mindfulness-Based Cognitive Therapy
- Trial name
- MBCT (NCT00943033)
- Testing
- Mindfulness-Based Cognitive Therapy
- Volunteers
- 48 people
- Sponsor
- Binghamton University
Bipolar Disorder
Prevention of Relapse & Recurrence of Bipolar Depression
The purpose of this study is to determine whether the long-term use of combined antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in preventing the relapse and recurrence of bipolar…
- Trial name
- NCT00961961
- Testing
- Lithium / Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 177 people
- Sponsor
- University of Pennsylvania
Depression, Major Depressive Disorder
Stress Generation and Recurrent Depression: The Role of Differential Treatment Response
Depression affects over one million people in Canada, resulting in $14.4 billion per year in costs to Canadian society. In order to prevent this often lifelong disorder, it is critically important to identify risk factors for the…
- Trial name
- NCT00745017
- Testing
- Cognitive Behavioral Therapy, Interpersonal Therapy, Antidepressant medication
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Centre for Addiction and Mental Health
Chronic Depression, Persistent Depressive Disorder
Intensive Psychotherapy for Chronic Depression
The study evaluates whether Intensive psychotherapy show superior effect on chronic depression over TAU
- Conditions
- Chronic Depression, Persistent Depressive Disorder, Recurrent Major Depression
- Trial name
- NCT05221567
- Testing
- Psychotherapy
- Volunteers
- 280 people
- Sponsor
- Modum Bad
Depressive Disorder, Major
Mindfulness Based Cognitive Therapy for Recurrent Depression
The purpose of this study is to investigate the effectiveness and possible mediating factors of Mindfulness Based Cognitive Therapy (MBCT) for recurrent depression.
- Trial name
- NCT01038765
- Testing
- Mindfulness Based Cognitive Therapy
- Where
- Netherlands
- Volunteers
- 220 people
- Sponsor
- Radboud University Medical Center
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Depression, Recurrent Depression
Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression
Group based cognitive behavioural therapy (CBT) is an effective treatment of depression, however, one third of patients do not respond satisfactorily (McDermut, Miller, \& Brown, 2001), and relapse rates around 30% have been…
- Trial name
- RuCoD (NCT02278224)
- Testing
- Group based rumination focused CBT, Group based CBT
- Where
- Denmark
- Volunteers
- 131 people
- Sponsor
- University of Copenhagen
Major Depressive Disorder, Recurrent, in Remission, Major Depressive Disorder, Recurrent, Mild
Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference
Objectives: To evaluate the clinical- and cost-effectiveness of two delivery formats of mindfulness-based cognitive therapy (MBCT) - (i) MBCT delivered through eight videoconference group sessions (group MBCT), and (ii) MBCT…
- Conditions
- Major Depressive Disorder, Recurrent, in Remission, Major Depressive Disorder, Recurrent, Mild, Major Depressive Disorder, Recurrent, Moderate
- Trial name
- BECOME (NCT06832605)
- Testing
- Group Mindfulness-Based Cognitive Therapy, Mindfulness-Based Cognitive Therapy Self-Help, Treatment as Usual (TAU)
- Where
- 5 sites in Spain
- Volunteers
- 342 people
- Sponsor
- Fundació Sant Joan de Déu
Depressive Disorder, Depressive Disorder, Major Depressive Disorder
Detection Algorithm for Recurrence or Relapse of Depression Thanks to a Smartwach
Globally, 3.8% of the population, or approximately 280 million people, suffer from depression. In France, 12.5% of adults experienced a major depressive episode (MDE) in 2021, with women being twice as affected as men.
- Conditions
- Depressive Disorder, Depressive Disorder, Major Depressive Disorder, Depressive Disorder Not Otherwise Specified (NOS)
- Trial name
- DALIA (NCT06789822)
- Testing
- Invitation to wear the smartwatch
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Dalia Care